Articles

Anterior and posterior capsulorhexis in children

The LENSTAR LS900® was introduced at last year's ESCRS and provides the user with a complete biometrical assessment of the patient?s eye in a single measurement procedure, including lens thickness, anterior chamber depth (lens position) and retinal thickness.

Four new products launched at today's show to help facilitate surgeons? daily work included a new modular phaco machine for cataract surgery and solution for posterior vitrectomy, a new single-piece hydrophilic pre-loaded IOL, a new viscoelastic and a new lubricant and contact agent for the protection of the corneal surface during surgery. The quartet have all been launched by Croma.

Hoya Surgical Products now has, what it claims to be, the Sharpest Edge on the market. The yellow aspheric blue-light filter IOLS iSymm has undergone a unique manufacturing process which makes it the sharpest of all commercially available IOLs currently in the market.

Interim results from a Phase II study by Gene Signal suggest that antisense oligonucleotide GS-101 is safe and effective at inhibiting abnormal corneal new blood vessel growth.

The first European Master's degree in Clinical and Surgical Ophthalmology, a prestigious international project of advanced studies for ophthalmological professionals, was presented in Lugano (Switzerland) by the European School for Advanced Studies in Ophthalmology.

$400 million in cash has secured the acquisition of Visiogen for Abbott and secured the latter a next-generation accommodating IOL technology to help presbyopia in cataract patients.

A new study conducted by researchers at the University of Aberdeen, Scotland, has found that the brain predicts the consequences of eye movement even before the eyes take in a new scene.

The pathology of glaucoma is likely to be related to the presence and levels of selenium, according to the results of a study published in the August issue of the British Journal of Ophthalmology.

High levels of the enzyme arginase contributes to vascular eye damage, and therapies to lower its levels could halt progression of diabetic retinopathy (DR), according to researchers at the Medical College of Georgia (MCG) School of Medicine, USA.

Iridex has commenced shipment of its IQ 577 laser systems which is designed to treat vision-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma.

In a head-to-head comparison of six OCT devices, the Spectralis spectral domain OCT (Heidelberg Engineering) showed the lowest co-efficient of variation in a test-retest study.

Before and after cataract surgery

Are the years of research and advocacy at last reaping rewards?

Leadership and evidence-based approaches to alleviate the burden of blindness

The Seeing is Believing initiative at Stardard Chartered Bank

The background to the Egyptian Menia study

World Sight Day is an international day of awareness to focus attention on the global issue of avoidable blindness and visual impairment. This year the theme is Gender and Eye Health – equal access to care

Whilst VISION 2020 is a global initiative it always had a focus on Europe too

Changes of culture and strategy at Pfizer are good news for ophthalmology

A Kenyan doctor's perspective

A pioneering model of community health

A look at the VISION 2020 Gender Discussion Group

The MECTIZAN donation programme to fight river blindness

Forty five millon people are blind worldwide, yet 80% of blindness is avoidable

According to a report in the August issue of Archives of Ophthalmology, there are eight factors that may predict whether a choroidal nevus-a benign, flat, pigmented growth inside the eye and beneath the retina-may develop into melanoma.

Allergan Inc. expects its ketorolac tromethamine ophthalmic solution 0.45% (Acuvail) to be available in the United States in September. The preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the treatment of pain and inflammation after cataract surgery and received FDA approval at the end of July, the company announced.

Results from the Omeros Corporation for the Phase I/Phase II clinical trial of OMS302, a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis) are said to be promising.

Researchers in Cleveland have discovered the first gene associated with the formation of age-related cataracts. EphA2 encodes an enzyme that plays a role in the repair of proteins in the lens of the eye after they become damaged and clump together, according to the investigators.

Partial sections of vision were recently restored to a blind woman's retina through the use of gene therapy.